BackAbivax Overview

Abivax Gross Profit

Track Abivax's gross profit ($970K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Gross Profit

$0

As of Jun 30, 2026

Annual Gross Profit (TTM)

$973310.00
↓ 63.33% YoY

Trailing 12 months ending Jun 30, 2026

Average Gross Profit (Comparison Companies)

Gross Profit History

Gross Profit Comparison

Annual Gross Profit Growth Rate (%)

Annual Gross Profit Growth (Absolute)

Abivax (ABVX) FAQ

The latest gross profit for ABVX is $970K as of June 2026. That compares with $2.7M in the prior-year period — down 63.3% year over year. That is below the Healthcare sector average of $4.6T. Investors often review this figure alongside Abivax's historical trend and sector peers before judging valuation or financial health.

Over the past year, ABVX's gross profit moved from $2.7M to $970K — a 63.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Abivax's operating scale or balance-sheet position.

Against Healthcare companies, ABVX currently prints $970K for gross profit, while the sector average sits near $4.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Abivax's growth, margins, and balance sheet.

A gross profit figure of $970K for ABVX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $4.6T. Explore the charts below for those layers of context.

After noting ABVX's gross profit ($970K), review year-over-year change from $2.7M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.